Collegium Pharmaceutical (COLL) Given a $35.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald set a $35.00 price target on Collegium Pharmaceutical (NASDAQ:COLL) in a research note released on Friday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

A number of other research firms also recently weighed in on COLL. BidaskClub downgraded Collegium Pharmaceutical from a buy rating to a hold rating in a report on Thursday, June 28th. Zacks Investment Research upgraded Collegium Pharmaceutical from a sell rating to a hold rating in a report on Wednesday, August 8th. ValuEngine downgraded Collegium Pharmaceutical from a strong-buy rating to a buy rating in a report on Monday, July 2nd. HC Wainwright reiterated a buy rating on shares of Collegium Pharmaceutical in a report on Monday, September 17th. Finally, Janney Montgomery Scott set a $27.00 target price on Collegium Pharmaceutical and gave the stock a buy rating in a report on Monday, August 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $31.71.

Shares of NASDAQ:COLL opened at $15.77 on Friday. Collegium Pharmaceutical has a 1 year low of $9.01 and a 1 year high of $29.90. The stock has a market cap of $508.29 million, a P/E ratio of -6.23 and a beta of 0.41. The company has a current ratio of 0.82, a quick ratio of 0.78 and a debt-to-equity ratio of 3.94.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.02. Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. The firm had revenue of $73.10 million for the quarter, compared to the consensus estimate of $72.21 million. The company’s revenue for the quarter was up 1930.6% compared to the same quarter last year. analysts expect that Collegium Pharmaceutical will post -1.49 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the stock. Northern Trust Corp grew its stake in shares of Collegium Pharmaceutical by 78.5% in the 2nd quarter. Northern Trust Corp now owns 526,499 shares of the specialty pharmaceutical company’s stock worth $12,557,000 after buying an additional 231,463 shares during the last quarter. Castleark Management LLC lifted its position in Collegium Pharmaceutical by 31.9% in the 2nd quarter. Castleark Management LLC now owns 292,878 shares of the specialty pharmaceutical company’s stock valued at $6,985,000 after acquiring an additional 70,820 shares in the last quarter. Granahan Investment Management Inc. MA lifted its position in Collegium Pharmaceutical by 192.3% in the 2nd quarter. Granahan Investment Management Inc. MA now owns 127,460 shares of the specialty pharmaceutical company’s stock valued at $3,040,000 after acquiring an additional 83,860 shares in the last quarter. Millennium Management LLC lifted its position in Collegium Pharmaceutical by 1,171.8% in the 2nd quarter. Millennium Management LLC now owns 361,035 shares of the specialty pharmaceutical company’s stock valued at $8,611,000 after acquiring an additional 332,647 shares in the last quarter. Finally, Macquarie Group Ltd. lifted its position in Collegium Pharmaceutical by 9.9% in the 2nd quarter. Macquarie Group Ltd. now owns 2,588,356 shares of the specialty pharmaceutical company’s stock valued at $61,732,000 after acquiring an additional 233,598 shares in the last quarter. Institutional investors own 93.57% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Story: The Role of a Fiduciary and Individual Investors

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply